Efektivitas in vitro Alfa Mangostin Pada Pertumbuhan Bakteri Uropatogen Escherichia coli Multiresisten

• Main Authors: Maya Dian Rakhmawatie, Afiana Rohmani, Fariz Wafaul Ahyar
• Format: Article
• Language: English
• Published: Universitas Sultan Agung Semarang 2017-04-01
• Series: Sains Medika
• Subjects: MDR; antibiotic; Garcinia mangostana L.
• Online Access: http://jurnal.unissula.ac.id/index.php/sainsmedika/article/view/1002

Background. The incidence of Multi Drug Resistant (MDR) in extraintestinal E. coli has become a global problem in the world. In Indonesia, the greatest resistance to the uropathogen E. coli is resistant to ampicillin (91.9%), ciprofloxacin (83.7%) and cefixime (67.6%). Therefore it takes effort for the treatment of MDR uropathogen E. coli, one of them are development of new antibiotics from herbal isolates of Garcinia mangostana L., α-mangosteen. This study examined the activity of α-mangosteen in vitro on the growth of MDR uropathogen E. coli. Methods. Treatment of uropathogen E. coli is performed in vitro, using α-mangosteen with a range of levels 14 - 450 µg/mL. The antibacterial activity of α-mangosteen is measured by determine at the growth or death of bacteria at each concentration using indirect methods, which is absorbance reading. Uropathogen E. coli that had been treated with various concentration of α-mangosteen incubated for 18-20 hours, then read an absorbance at wavelenght 625 nm using a spectrophotometer. Result. The Minimal Inhibitory Concentration (MIC) of α-mangosteen in this study was 450 µg/mL. Based on the linear regression (STATA 13.1) relationship between concentration of α-mangosteen and activity of growth inhibition of bacteria, obtained the F test value 0.0001 < 0.05, states that all concentrations of α-mangosteen simultaneously have a significant influence on the growth of uropathogen E. coli. Conclusion. MIC value is relatively large causing α-mangosteen activity against Gram-negative bacteria needs to be studied further. Potentially relevant activity in the clinic will occur if the value of in vitro MIC < 100 µg/mL. Likewise, the pharmaceutical industry prefers the development of antibiotics that have in vitro MIC values ≤ 2 µg/mL.